Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

Experimental Swine Models for Vascularized Composite Allotransplantation and Immunosuppression: A Systematic Review and Case Report of a Novel Heterotopic Hemifacial Swine Model

Knoedler L., Klimitz FJ., Huelsboemer L., Niederegger T., Schaschinger T., Knoedler S.

Systematic Review on Face & Skin, published in Transpl Int (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Transpl Int (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40799314
PMCID
PMC12341719
DOI
10.3389/ti.2025.14520
Citations
3

Abstract (original English)

Lifelong immunosuppression is necessary to prevent rejection in vascularized composite allotransplantation (VCA). Animal models play a pivotal role in developing innovative immunosuppressive strategies. This systematic review and case report focuses on the most impactful swine VCA models while offering insights gained from the Yale Swine Allotransplantation Vascularized Experiment (Y-SAVE). 22 studies on swine VCA models were included. Key swine breeds included SLA-matched and mismatched MGH miniature swine, Yucatan miniature swine, and outbred domestic swine. Transplantation models varied, with 10 (45%) using osteomyocutaneous flaps and only 2 (9%) involving hemifacial flaps. While 16 (73%) studies utilized heterotopic models, 5 (23%) relied on orthotopic models. Novel strategies such as preconditioning and localized drug delivery emerged, alongside immunosuppression regimens combining tacrolimus with experimental therapies. We further introduced a modified heterotopic hemiface VCA model, demonstrating its feasibility for studying immune dynamics in facial transplants while preserving oral function and enabling serial skin and mucosal biopsies. Overall, our review highlights a notable gap in models that specifically investigate facial VCAs. Given the unique immunological environment of facial allografts, models such as the heterotopic hemiface transplant may offer critical ins

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
FaceAnimalsSwineSwine, MiniatureImmunosuppressive AgentsTransplantation, HeterotopicModels, AnimalGraft RejectionFacial TransplantationVascularized Composite Allotransplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research